U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07357623) titled 'Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors' on Aug. 07, 2025.
Brief Summary: The goal of this clinical trial is to investigate if chemotherapy works with surufatinib to treat pulmonary neuroendocrine tumors. It will also learn about the safety of this combination regimen. The main questions it aims to answer are:
Does chemotherapy combined with surufatinib could bring more survival benefits (ie. higher response rate or longer survival time) for patients with pulmonary neuroendocrine tumors? Is this combination regimen safe?
Researchers will compare chemotherapy plus suruf...